HRP20250727T1 - Inhibitori metalotioneina za liječenje dijabetesa, hepatitisa, i/ili upalne bolesti jetre - Google Patents

Inhibitori metalotioneina za liječenje dijabetesa, hepatitisa, i/ili upalne bolesti jetre

Info

Publication number
HRP20250727T1
HRP20250727T1 HRP20250727TT HRP20250727T HRP20250727T1 HR P20250727 T1 HRP20250727 T1 HR P20250727T1 HR P20250727T T HRP20250727T T HR P20250727TT HR P20250727 T HRP20250727 T HR P20250727T HR P20250727 T1 HRP20250727 T1 HR P20250727T1
Authority
HR
Croatia
Prior art keywords
composition
use according
subject
diabetes
liver disease
Prior art date
Application number
HRP20250727TT
Other languages
English (en)
Croatian (hr)
Inventor
Michael A. Lynes
Yu-Hua Tseng
Matthew D. LYNES
Original Assignee
University Of Connecticut
Joslin Diabetes Center, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Connecticut, Joslin Diabetes Center, Inc. filed Critical University Of Connecticut
Publication of HRP20250727T1 publication Critical patent/HRP20250727T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HRP20250727TT 2018-01-17 2019-01-17 Inhibitori metalotioneina za liječenje dijabetesa, hepatitisa, i/ili upalne bolesti jetre HRP20250727T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862618332P 2018-01-17 2018-01-17
EP19703874.8A EP3740282B1 (en) 2018-01-17 2019-01-17 Metallothionein inhibitors for treating diabetes, hepatitis, and/or inflammatory liver disease
PCT/US2019/013934 WO2019143767A1 (en) 2018-01-17 2019-01-17 Methods for treating diabetes, hepatitis, and/or inflammatory liver disease

Publications (1)

Publication Number Publication Date
HRP20250727T1 true HRP20250727T1 (hr) 2025-10-24

Family

ID=65324621

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20250727TT HRP20250727T1 (hr) 2018-01-17 2019-01-17 Inhibitori metalotioneina za liječenje dijabetesa, hepatitisa, i/ili upalne bolesti jetre

Country Status (20)

Country Link
US (3) US11866488B2 (https=)
EP (2) EP4596042A3 (https=)
JP (2) JP7486423B2 (https=)
KR (2) KR102937161B1 (https=)
CN (2) CN120267797A (https=)
AU (2) AU2019209491B2 (https=)
BR (1) BR112020014346A2 (https=)
CA (1) CA3088661A1 (https=)
EA (1) EA202091533A1 (https=)
ES (1) ES3033317T3 (https=)
HR (1) HRP20250727T1 (https=)
HU (1) HUE072418T2 (https=)
IL (2) IL316486A (https=)
MX (1) MX2020007384A (https=)
PH (1) PH12020551076A1 (https=)
PL (1) PL3740282T3 (https=)
RS (1) RS66918B1 (https=)
SG (1) SG11202006421RA (https=)
SM (1) SMT202500233T1 (https=)
WO (1) WO2019143767A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020234718A1 (en) 2019-03-13 2023-05-18 Tearsolutions, Inc. Compositions and methods for promoting islet viability and enhancing insulin secretion
EP3999531A1 (en) * 2019-07-15 2022-05-25 University of Connecticut Metallothionein antibodies and their use
CN110551726B (zh) * 2019-09-06 2021-04-09 上海市肺科医院 一种结核杆菌阿拉伯半乳聚糖适配子及其应用
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
KR102191405B1 (ko) * 2020-09-15 2020-12-16 주식회사 에이스바이오메드 간 질환 예방 또는 치료용 조성물
CN115317502B (zh) * 2021-12-21 2023-07-07 青岛市市立医院 一种线性硬毛藻提取的粗多糖在制备非酒精性脂肪性肝药物中的应用
WO2025226837A1 (en) * 2024-04-24 2025-10-30 University Of Connecticut Anti-bacterial metallothionein antibodies and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US20030007973A1 (en) 2001-06-22 2003-01-09 Lynes Michael A. Methods and compositions for manipulation of the immune response using anti-metallothionein antibody
CA2658673A1 (en) 2005-07-27 2008-02-01 Gerald J. Prud'homme Composition and method for prevention and treatment of type i and type ii diabetes
WO2011050052A2 (en) * 2009-10-20 2011-04-28 Georgia State University Research Foundation, Inc. Protein agent for diabetes treatment and beta cell imaging
CA2813711A1 (en) 2010-10-14 2012-04-19 Immunahr Ab 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as ahr activators.
CA2840282C (en) 2011-07-08 2018-11-13 Universiteit Gent Use of antagonists targeting metallothionein to treat intestinal inflammation
WO2014172606A1 (en) * 2013-04-19 2014-10-23 The Brigham And Women's Hospital, Inc. Methods for modulating immune responses during chronic immune conditions by targeting metallothioneins
TR201402685A1 (tr) 2014-03-06 2015-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vildagliptinin farmasotik formulasyonları.
EP3149049B1 (en) * 2014-05-27 2022-10-26 The University Of Queensland Il-22 for use in treating metabolic disorders
TW201613949A (en) 2014-08-07 2016-04-16 Regulus Therapeutics Inc Targeting microRNAs for metabolic disorders

Also Published As

Publication number Publication date
CN111801140A (zh) 2020-10-20
BR112020014346A2 (pt) 2020-12-08
SMT202500233T1 (it) 2025-07-22
CA3088661A1 (en) 2019-07-25
CN120267797A (zh) 2025-07-08
IL276097B2 (en) 2025-04-01
ES3033317T3 (en) 2025-08-01
EP4596042A3 (en) 2025-11-05
US20240025981A1 (en) 2024-01-25
JP2024028454A (ja) 2024-03-04
KR20260042289A (ko) 2026-03-30
US11866488B2 (en) 2024-01-09
CN111801140B (zh) 2025-05-16
JP7486423B2 (ja) 2024-05-17
IL276097A (en) 2020-08-31
IL316486A (en) 2024-12-01
US12583916B2 (en) 2026-03-24
PL3740282T3 (pl) 2025-07-21
KR20200110659A (ko) 2020-09-24
AU2022215285B2 (en) 2024-08-29
MX2020007384A (es) 2020-10-19
US20200369757A1 (en) 2020-11-26
US20240067710A1 (en) 2024-02-29
EP3740282C0 (en) 2025-03-26
AU2022215285A1 (en) 2022-09-29
IL276097B1 (en) 2024-12-01
AU2019209491A1 (en) 2020-07-23
WO2019143767A1 (en) 2019-07-25
HUE072418T2 (hu) 2025-11-28
EP3740282B1 (en) 2025-03-26
EA202091533A1 (ru) 2020-11-16
PH12020551076A1 (en) 2021-08-16
JP2021511296A (ja) 2021-05-06
SG11202006421RA (en) 2020-08-28
AU2019209491B2 (en) 2022-05-19
EP4596042A2 (en) 2025-08-06
KR102937161B1 (ko) 2026-03-10
EP3740282A1 (en) 2020-11-25
RS66918B1 (sr) 2025-07-31

Similar Documents

Publication Publication Date Title
HRP20250727T1 (hr) Inhibitori metalotioneina za liječenje dijabetesa, hepatitisa, i/ili upalne bolesti jetre
Lin et al. Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial
Lam et al. Obesity, obstructive sleep apnoea and metabolic syndrome
Sharma et al. Faricimab: expanding horizon beyond VEGF
Neuschwander-Tetri et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Bullone et al. Fluticasone/salmeterol reduces remodelling and neutrophilic inflammation in severe equine asthma
Nishizawa et al. IGF-I induces senescence of hepatic stellate cells and limits fibrosis in a p53-dependent manner
Yu et al. Erianin inhibits high glucose-induced retinal angiogenesis via blocking ERK1/2-regulated HIF-1α-VEGF/VEGFR2 signaling pathway
Wang et al. FXR: a metabolic regulator and cell protector
Loguercio et al. Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial
Cassidy et al. Nonalcoholic steatohepatitis (NASH) drugs market
Ogata et al. Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab
HRP20180445T1 (hr) Il-22 za uporabu u liječenju mikrobnih poremećaja
Zhang et al. Circulating asprosin levels are increased in patients with type 2 diabetes and associated with early-stage diabetic kidney disease
Park et al. Empagliflozin and dulaglutide are effective against obesity-induced airway hyperresponsiveness and fibrosis in a murine model
Sans et al. The differential expression of cide family members is associated with nafld progression from steatosis to steatohepatitis
MX337644B (es) Anticuerpos anti-angptl3 y usos de los mismos.
HRP20150290T1 (hr) Metoda lijeäśenja karcinoma prostate s gnrh antagonistom degareliksom
Zhang et al. Recombinant adiponectin ameliorates liver ischemia reperfusion injury via activating the AMPK/eNOS pathway
Zhang et al. The effect of moderate hepatic impairment on the pharmacokinetics of ipragliflozin, a novel sodium glucose co-transporter 2 (SGLT2) inhibitor
Chen et al. Targeting SYK of monocyte-derived macrophages regulates liver fibrosis via crosstalking with Erk/Hif1α and remodeling liver inflammatory environment
Meng et al. FGF21 ameliorates hepatic fibrosis by multiple mechanisms
Wagner et al. Nuclear bile acid receptor farnesoid X receptor meets nuclear factor‐κB: New insights into hepatic inflammation
Li et al. The ANGPTL4-HIF-1α loop: a critical regulator of renal interstitial fibrosis
Wepler et al. Effects of the PPAR-β/δ agonist GW0742 during resuscitated porcine septic shock